Advice
following a resubmission:
fezolinetant (Veoza®) is accepted for restricted use within NHSScotland.
Indication under review: for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
SMC restriction: for use in patients for whom hormone replacement therapy (HRT) is not deemed suitable.
In a phase IIIb study fezolinetant significantly reduced the frequency of VMS in menopausal participants considered unsuitable for hormone therapy compared with placebo. In addition, in two identical phase III studies fezolinetant significantly reduced the frequency and severity of VMS compared with placebo in menopausal participants.
Medicine details
- Medicine name:
- fezolinetant (Veoza)
- SMC ID:
- SMC2898
- Indication:
For treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 13 July 2026